Gyre Therapeutics Inc. (GYRE)
Gyre Therapeutics Statistics
Share Statistics
Gyre Therapeutics has 86.33M shares outstanding. The number of shares has increased by 0.96% in one year.
| Shares Outstanding | 86.33M |
| Shares Change (YoY) | 0.96% |
| Shares Change (QoQ) | 0.59% |
| Owned by Institutions (%) | 1.94% |
| Shares Floating | 16.27M |
| Failed to Deliver (FTD) Shares | 3.19K |
| FTD / Avg. Volume | 2.27% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 85.2 and the forward PE ratio is 6.8. Gyre Therapeutics's PEG ratio is -0.78.
| PE Ratio | 85.2 |
| Forward PE | 6.8 |
| PS Ratio | 9.74 |
| Forward PS | 1.3 |
| PB Ratio | 16.26 |
| P/FCF Ratio | -172.88 |
| PEG Ratio | -0.78 |
Enterprise Valuation
Gyre Therapeutics has an Enterprise Value (EV) of 1.02B.
| EV / Sales | 9.64 |
| EV / EBITDA | 63.07 |
| EV / EBIT | -279.99 |
| EV / FCF | -171.16 |
Financial Position
The company has a current ratio of 3.32, with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.32 |
| Quick Ratio | 2.99 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.1 |
| Debt / FCF | -0.27 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 19.09% and Return on Invested Capital is 11.69%.
| Return on Equity | 19.09% |
| Return on Assets | 9.64% |
| Return on Invested Capital | 11.69% |
| Revenue Per Employee | $182.65K |
| Profits Per Employee | $20.87K |
| Employee Count | 579 |
| Asset Turnover | 0.84 |
| Inventory Turnover | 0.61 |
Taxes
| Income Tax | 5.32M |
| Effective Tax Rate | 22.91% |
Stock Price Statistics
The stock price has increased by -42.75% in the last 52 weeks. The beta is 2.41, so Gyre Therapeutics's price volatility has been higher than the market average.
| Beta | 2.41 |
| 52-Week Price Change | -42.75% |
| 50-Day Moving Average | 10.06 |
| 200-Day Moving Average | 11.94 |
| Relative Strength Index (RSI) | 51.54 |
| Average Volume (20 Days) | 140.49K |
Income Statement
In the last 12 months, Gyre Therapeutics had revenue of 105.76M and earned 12.09M in profits. Earnings per share was 0.14.
| Revenue | 105.76M |
| Gross Profit | 101.87M |
| Operating Income | 16.16M |
| Net Income | 12.09M |
| EBITDA | 16.16M |
| EBIT | 16.23M |
| Earnings Per Share (EPS) | 0.14 |
Balance Sheet
The company has 11.81M in cash and 1.6M in debt, giving a net cash position of 10.21M.
| Cash & Cash Equivalents | 11.81M |
| Total Debt | 1.6M |
| Net Cash | 10.21M |
| Retained Earnings | -73.45M |
| Total Assets | 125.41M |
| Working Capital | 45.27M |
Cash Flow
In the last 12 months, operating cash flow was -3.64M and capital expenditures -2.31M, giving a free cash flow of -5.96M.
| Operating Cash Flow | -3.64M |
| Capital Expenditures | -2.31M |
| Free Cash Flow | -5.96M |
| FCF Per Share | -0.07 |
Margins
Gross margin is 96.33%, with operating and profit margins of 15.28% and 11.43%.
| Gross Margin | 96.33% |
| Operating Margin | 15.28% |
| Pretax Margin | 21.95% |
| Profit Margin | 11.43% |
| EBITDA Margin | 15.28% |
| EBIT Margin | 15.28% |
| FCF Margin | -5.63% |
Dividends & Yields
GYRE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 1.17% |
| FCF Yield | -0.58% |
Analyst Forecast
Currently there are no analyst rating for GYRE.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Oct 31, 2023. It was a backward split with a ratio of 1:15.
| Last Split Date | Oct 31, 2023 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | 15.34 |
| Piotroski F-Score | 3 |